BioTissue adds Chris Calcaterra to board as ocular health push continues

BioTissue has appointed ophthalmic veteran Chris Calcaterra to its Board of Directors as the company expands its focus on ocular health and biologic solutions for eye care. The move adds commercial and governance experience as BioTissue leans into its next phase of growth.

Why it matters: - BioTissue is adding seasoned ophthalmology leadership as it sharpens its focus on ocular health and ocular surface disease. - The board appointment brings commercial execution experience that could help BioTissue expand physician adoption and market reach. - The move comes as BioTissue works to reposition itself around biologic solutions for eye care.

What happened: - BioTissue announced the appointment of Chris Calcaterra to its Board of Directors on August 24, 2026. - Calcaterra will serve as an independent director. - Calcaterra is an ophthalmic industry veteran with experience in ophthalmology, medical technology, commercial strategy, physician engagement, market expansion and board governance. - BioTissue cited his tenure as chief operating officer of Glaukos Corporation, where he helped scale the company from an emerging ophthalmic innovator into a publicly traded company.

The details: - BioTissue said Calcaterra’s background aligns with the company’s next phase of growth in ocular health. - Ted Davis, president and CEO of BioTissue, said the company is sharpening its focus on ocular health and ocular surface disease. - Davis said BioTissue wants leaders with deep industry expertise and experience driving innovation and physician adoption. - Calcaterra said he wants to continue contributing time and experience to help patients and believes BioTissue has a strong foundation and a clear opportunity to advance ocular health. - BioTissue said Calcaterra’s appointment comes as the company expands its focus through the launch of CAM360 AmnioGraft, a shelf-stable cryopreserved amniotic membrane designed to promote healing in superficial eye conditions. - BioTissue also said its divestiture of the surgical business further positions the company to focus on biologic solutions for ocular surface conditions. - The company said these efforts build on its history in ocular surface disease and its goal of providing eye care professionals with biologic solutions designed to support treatment and improve patient outcomes. - More information is available on BioTissue’s website.

Between the lines: - The board addition signals BioTissue is prioritizing commercial scale and specialty-market execution, not just product development. - The combination of a board appointment, a product launch and a business divestiture suggests BioTissue is narrowing its strategy around higher-growth ocular health opportunities. - Calcaterra’s Glaukos background adds credibility with investors, physicians and potential commercial partners in ophthalmology.

What's next: - BioTissue is likely to keep building out its ocular health strategy around biologic treatments and physician adoption. - Calcaterra will join the board as the company continues to expand its impact in eye care. - BioTissue’s next milestones will likely center on commercial rollout, market penetration and execution of its refocused portfolio.

The bottom line: - BioTissue is betting that experienced ophthalmology leadership will help turn its narrowed focus on ocular health into growth.